Fox Run Management L.L.C. acquired a new position in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 9,700 shares of the biopharmaceutical company’s stock, valued at approximately $524,000.
Several other hedge funds have also recently made changes to their positions in the business. Sivik Global Healthcare LLC acquired a new position in shares of Portola Pharmaceuticals in the 2nd quarter worth approximately $1,685,000. State Street Corp raised its holdings in shares of Portola Pharmaceuticals by 5.3% in the 2nd quarter. State Street Corp now owns 2,085,838 shares of the biopharmaceutical company’s stock worth $117,164,000 after buying an additional 105,207 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Portola Pharmaceuticals in the 2nd quarter worth approximately $1,047,000. TIAA CREF Investment Management LLC raised its holdings in shares of Portola Pharmaceuticals by 4.0% in the 1st quarter. TIAA CREF Investment Management LLC now owns 223,924 shares of the biopharmaceutical company’s stock worth $8,776,000 after buying an additional 8,673 shares in the last quarter. Finally, Numeric Investors LLC acquired a new position in shares of Portola Pharmaceuticals in the 2nd quarter worth approximately $753,000. Institutional investors own 86.04% of the company’s stock.
Portola Pharmaceuticals, Inc. (PTLA) traded down $0.31 during trading hours on Tuesday, hitting $48.64. The stock had a trading volume of 811,000 shares, compared to its average volume of 994,438. Portola Pharmaceuticals, Inc. has a 1-year low of $17.15 and a 1-year high of $67.10. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.31 and a current ratio of 8.31.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.49) by $0.08. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The business had revenue of $3.83 million for the quarter, compared to analyst estimates of $4.71 million. During the same period last year, the company earned ($1.64) EPS. The firm’s revenue was down 58.9% on a year-over-year basis. analysts forecast that Portola Pharmaceuticals, Inc. will post -4.95 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was reported by Week Herald and is the property of of Week Herald. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://weekherald.com/2017/11/15/fox-run-management-l-l-c-takes-524000-position-in-portola-pharmaceuticals-inc-ptla.html.
A number of equities analysts have recently issued reports on the company. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $80.00 target price on shares of Portola Pharmaceuticals in a report on Tuesday, November 7th. Morgan Stanley reaffirmed an “overweight” rating and set a $81.00 price target (up from $75.00) on shares of Portola Pharmaceuticals in a report on Friday, October 6th. BidaskClub raised Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 25th. Credit Suisse Group AG raised Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 price target for the company in a report on Wednesday, August 23rd. Finally, Zacks Investment Research cut Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $65.15.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.